These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29018343)

  • 21. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
    Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
    J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study.
    Han S; Choi HY; Kim YH; Choi S; Kim S; Nam JY; Kim B; Song GS; Lim HS; Bae KS
    Gut Liver; 2023 Jan; 17(1):92-99. PubMed ID: 36317518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
    Robinson M; Horn J
    Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole.
    Kukulka M; Nudurupati S; Perez MC
    Therap Adv Gastroenterol; 2016 Nov; 9(6):759-769. PubMed ID: 27803731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model.
    Puchalski TA; Krzyzanski W; Blum RA; Jusko WJ
    J Clin Pharmacol; 2001 Mar; 41(3):251-8. PubMed ID: 11269565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of gastric acid secretion in the fetal rabbit.
    Yee LF; Andrews KJ; Calaustro EQ; Grady EF; Mulvihill SJ
    Surgery; 1995 Aug; 118(2):199-205. PubMed ID: 7638734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
    Inamori M; Togawa J; Takahashi K; Yoneda M; Fujisawa N; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
    J Gastroenterol Hepatol; 2003 Sep; 18(9):1034-8. PubMed ID: 12911659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
    Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
    Gastroenterology; 2000 Sep; 119(3):670-6. PubMed ID: 10982760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation.
    Yamano HO; Matsushita HO; Yanagiwara S
    J Gastroenterol Hepatol; 2008 Apr; 23(4):534-40. PubMed ID: 17725594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
    J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor.
    Lee RD; Mulford D; Wu J; Atkinson SN
    Aliment Pharmacol Ther; 2010 May; 31(9):1001-11. PubMed ID: 20180789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog.
    Postius S; Bräuer U; Kromer W
    Life Sci; 1991; 49(14):1047-52. PubMed ID: 1832475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers.
    Yu KS; Bae KS; Shon JH; Cho JY; Yi SY; Chung JY; Lim HS; Jang IJ; Shin SG; Song KS; Moon BS
    J Clin Pharmacol; 2004 Jan; 44(1):73-82. PubMed ID: 14681344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.
    Egan LJ; Myhre GM; Mays DC; Dierkhising RA; Kammer PP; Murray JA
    Aliment Pharmacol Ther; 2003 Jun; 17(12):1521-8. PubMed ID: 12823155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline.
    Koh A; Pak KC; Choi HY; Ryu S; Choi SE; Kim KS; Bae KS; Lim HS
    J Clin Pharmacol; 2019 Apr; 59(4):532-540. PubMed ID: 30452773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.
    Prapitpaiboon H; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2015; 16(10):4353-6. PubMed ID: 26028098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific labelling of gastric H+,K+-ATPase by omeprazole.
    Fryklund J; Gedda K; Wallmark B
    Biochem Pharmacol; 1988 Jul; 37(13):2543-9. PubMed ID: 2839196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.